Alaunos Narrows 9-Month Loss, Boosts Cash Amid Strategic Shift

TL;DR

**TCRT is a high-risk bet on an early-stage obesity drug, with improved cash but a long road to profitability and ongoing delisting concerns.**

AI Summary

Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $1.159 million for the three months ended September 30, 2025, a slight increase from the $1.127 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $3.283 million, an improvement from the $3.937 million loss in the prior year. Revenue remained negligible at $2 thousand for the nine months ended September 30, 2025, down from $6 thousand in 2024. Research and development expenses increased significantly to $1.002 million for the nine months ended September 30, 2025, compared to $448 thousand in 2024, reflecting a strategic reprioritization towards its small molecule oral obesity program. General and administrative expenses decreased to $2.318 million for the nine months ended September 30, 2025, from $3.615 million in 2024. The company's cash and cash equivalents increased to $1.938 million as of September 30, 2025, from $1.091 million at December 31, 2024, partly due to financing activities including the sale of Series A-1 and A-2 preferred stock, raising $500 thousand and $850 thousand respectively, and a registered direct offering yielding $998 thousand. Stockholders' equity stood at $2.803 million as of September 30, 2025, maintaining compliance with Nasdaq's $2.5 million listing requirement, though future compliance is uncertain given ongoing operating losses.

Why It Matters

This 10-Q reveals Alaunos Therapeutics is navigating a critical strategic reprioritization, shifting focus to its early-stage small molecule oral obesity program while facing significant financial constraints. For investors, the improved cash position to $1.938 million and compliance with Nasdaq's listing requirements are positive, but the continued net losses and early-stage pipeline present substantial risk. Employees face uncertainty given the company's 'going concern' warning and potential for dissolution if strategic transactions fail. Customers and the broader market will see little immediate impact, as the obesity program is preclinical, but its success could eventually challenge larger players in the competitive metabolic disease space.

Risk Assessment

Risk Level: high — Alaunos Therapeutics faces a high risk level due to its 'going concern' warning, indicating substantial doubt about its ability to continue operations without significant additional capital. The company's accumulated deficit reached $923.729 million as of September 30, 2025, and it continues to incur operating losses, with a net loss of $3.283 million for the nine months ended September 30, 2025. While it regained Nasdaq compliance with $2.803 million in stockholders' equity, the filing explicitly states, 'there can be no assurance that the Company will maintain compliance with Nasdaq's continued listing requirements in the future' due to limited cash runway and ongoing losses.

Analyst Insight

Investors should approach TCRT with extreme caution, recognizing it as a highly speculative investment. Given the early-stage nature of its obesity program and the 'going concern' warning, consider this a high-risk, high-reward play. Monitor closely for updates on strategic transactions or further capital raises, as these will be critical for the company's survival and potential future value.

Financial Highlights

debt To Equity

0.33

revenue

$2K

operating Margin

N/A

total Assets

$3.724M

total Debt

$0.921M

net Income

-$3.283M

eps

-$1.84

gross Margin

N/A

cash Position

$1.938M

revenue Growth

-66.7%

Key Numbers

• $1.159M — Net Loss (Q3 2025) (Increased from $1.127M in Q3 2024, indicating continued operational losses.)
• $3.283M — Net Loss (YTD 2025) (Improved from $3.937M in YTD 2024, showing some cost control or reduced activity.)
• $1.938M — Cash and Cash Equivalents (Increased from $1.091M at Dec 31, 2024, providing a short-term liquidity boost.)
• $2.803M — Stockholders' Equity (Maintains compliance with Nasdaq's $2.5M minimum, but future compliance is uncertain.)
• $1.002M — R&D Expenses (YTD 2025) (Significantly increased from $448K in YTD 2024, reflecting investment in the obesity program.)
• $2.318M — G&A Expenses (YTD 2025) (Decreased from $3.615M in YTD 2024, indicating efforts to reduce overhead.)
• $923.729M — Accumulated Deficit (Highlights the company's long history of losses and need for substantial future profitability.)
• 2,231,829 — Outstanding Shares (As of November 14, 2025, indicating potential for dilution from future capital raises.)
• $500K — Series A-1 Preferred Stock Sale (Part of financing activities to bolster cash reserves.)
• $850K — Series A-2 Preferred Stock Sale (Further capital raised to support operations.)

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — registrant of the 10-Q filing
• Nasdaq Capital Market (regulator) — stock exchange where TCRT is listed
• $1.159 million (dollar_amount) — net loss for the three months ended September 30, 2025
• $3.283 million (dollar_amount) — net loss for the nine months ended September 30, 2025
• $1.938 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $2.803 million (dollar_amount) — stockholders' equity as of September 30, 2025
• $2.5 million (dollar_amount) — Nasdaq Listing Rule 5550(b)(1) minimum stockholders' equity requirement
• $1.002 million (dollar_amount) — research and development expenses for the nine months ended September 30, 2025
• $923.729 million (dollar_amount) — accumulated deficit as of September 30, 2025
• September 30, 2025 (date) — end of the reporting period for the 10-Q

FAQ

Risk Factors

• Ongoing Operating Losses and Need for Future Financing [high — financial]: The company reported net losses of $1.159 million for Q3 2025 and $3.283 million year-to-date. While cash increased to $1.938 million due to financing, the accumulated deficit stands at $923.729 million. Continued losses necessitate future capital raises, which could lead to dilution and uncertainty regarding continued operations.
• Nasdaq Listing Compliance Uncertainty [medium — financial]: Stockholders' equity was $2.803 million as of September 30, 2025, meeting the Nasdaq minimum of $2.5 million. However, ongoing operating losses pose a significant risk to maintaining this compliance in the future, potentially leading to delisting.
• Strategic Reprioritization and R&D Investment [medium — operational]: R&D expenses increased significantly to $1.002 million for the nine months ended September 30, 2025, from $448 thousand in the prior year, driven by a strategic shift towards the small molecule oral obesity program. This increased investment carries the risk of not yielding the desired results or facing intense competition.
• Dependence on Equity Financing [high — financial]: The company raised $2.348 million through preferred stock sales and a direct offering in the period. This reliance on external financing, particularly equity, exposes the company to market volatility and investor sentiment, impacting its ability to fund operations and development.
• Negligible Revenue and Competitive Landscape [medium — market]: Revenue remains minimal at $2 thousand for the nine months ended September 30, 2025. The company operates in a highly competitive biopharmaceutical sector, and its ability to generate substantial revenue and achieve profitability is uncertain.

Industry Context

Alaunos Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on developing novel therapies. The sector is characterized by long development cycles, significant R&D investment, and high failure rates. Companies often rely on external financing and strategic partnerships to advance their pipelines.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Alaunos is subject to stringent regulatory oversight from bodies like the FDA. Successful development and approval of its therapies are critical. Maintaining Nasdaq listing compliance is also a key regulatory consideration, with potential delisting risks if financial thresholds are not met.

What Investors Should Do

1. Monitor R&D progress and clinical trial results for the obesity program.
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate Nasdaq listing compliance risks.
4. Analyze the competitive landscape for obesity treatments.

Key Dates

• 2025-09-30: Balance Sheet Date — Reflects increased cash position and stockholders' equity, maintaining Nasdaq compliance for the period.
• 2025-09-30: End of Nine-Month Period — Shows significant increase in R&D expenses and decrease in G&A expenses, with a net loss of $3.283 million.
• 2024-12-31: Prior Year End Balance Sheet Date — Provides a baseline for comparison of asset and liability changes, with lower cash and equity.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's long-standing history of operating at a loss, with a current deficit of $923.729 million.)

Stockholders' equity

The residual interest in the assets of an entity after deducting all its liabilities. (At $2.803 million, it meets Nasdaq's minimum listing requirement of $2.5 million, but future compliance is at risk due to ongoing losses.)

Additional paid-in capital

The amount of capital that shareholders have paid to the corporation in excess of the par value of the stock. (Represents a significant portion of the company's equity, largely derived from past stock issuances, totaling $926.530 million.)

Weighted average common shares outstanding

The number of common shares outstanding over a period, adjusted for dilutive effects. (Increased to 1,822,500 for the nine months of 2025 from 1,601,252 in 2024, reflecting share issuances from financing activities.)

Preferred stock

Stock that has a priority over common stock in terms of dividends and asset distribution in case of liquidation. (The company issued Series A-1 and A-2 preferred stock, raising $500 thousand and $850 thousand respectively, contributing to its cash position.)

Year-Over-Year Comparison

Compared to the prior year, Alaunos Therapeutics has seen a significant increase in R&D expenses ($1.002M vs $448K YTD) due to strategic reprioritization towards its obesity program, while G&A expenses have decreased ($2.318M vs $3.615M YTD). Revenue remains negligible ($2K vs $6K YTD). The company's cash position has improved ($1.938M vs $1.091M), and stockholders' equity has increased ($2.803M vs $2.063M), partly due to successful financing rounds, though net losses persist ($3.283M vs $3.937M YTD).

Key Financial Figures

• $0.001 — hares of the registrant's common stock, $0.001 par value, was 2,231,829 shares. SPEC
• $2,500,000 — our stockholder's equity falling below $2,500,000 as required by Nasdaq Listing Rule 5550
• $3.66 m — 025, evidencing stockholders' equity of $3.66 million, the Listing Qualifications staff
• $2,823,000 — losed. As of September 30, 2025, we had $2,823,000 in stockholder' equity resulting in com

Filing Documents

• tcrt-20250930.htm (10-Q) — 1499KB
• tcrt-ex31_1.htm (EX-31.1) — 14KB
• tcrt-ex32_1.htm (EX-32.1) — 8KB
• 0001193125-25-282988.txt ( ) — 5656KB
• tcrt-20250930.xsd (EX-101.SCH) — 1028KB
• tcrt-20250930_htm.xml (XML) — 661KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 25 1

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Condensed Financial Statements (unaudited)

Item 1. Condensed Financial Statements (unaudited) Alaunos Therapeutics, Inc. CONDENSED BALANCE SHEETS (unaudited) (in thousands, except share and per share data) September 30, December 31, 2025 2024 ASSETS: Current assets: Cash and cash equivalents $ 1,938 $ 1,091 Receivables — 5 Prepaid expenses and other current assets, current 747 1,659 Total current assets 2,685 2,755 Property and equipment, net 97 Prepaid expenses and other assets, non current 942 — Total assets $ 3,724 $ 2,755 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 843 $ 516 Accrued expenses 78 176 Total current liabilities 921 692 Total liabilities $ 921 $ 692 Commitments and contingencies (Note 5) Stockholders' equity Series A-1 preferred stock $ 0.001 par value; 1,000 shares authorized, 500 and 0 shares issued and outstanding at September 30, 2025 and at December 31, 2024, respectively - - Series A-2 preferred stock $ 0.001 par value; 1,000 shares authorized, 850 and 0 shares issued and outstanding at September 30, 2025 and at December 31, 2024, respectively - - Common stock $ 0.001 par value; 50,000,000 shares authorized, 2,205,846 and 1,601,252 shares issued and outstanding at September 30, 2025 and at December 31, 2024, respectively 2 2 Additional paid-in capital 926,530 922,507 Accumulated deficit ( 923,729 ) ( 920,446 ) Total stockholders' equity 2,803 2,063 Total liabilities and stockholders' equity $ 3,724 $ 2,755 The accompanying notes are an integral part of these condensed financial statements. 2 Alaunos Therapeutics, Inc. CONDENSED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2025 2024 2025 2024 Revenue $ — $ — $ 2 $ 6 Operating expenses:

View Full Filing

View this 10-Q filing on SEC EDGAR